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PHENELZINE @-phenyl ethyl hydrazine
It is believed to be more rapid in action than iproniazid and it is said to act preferentially on cerebral tissues rather than on the liver, whereas iproniazid inhibits amine oxidase equally in the brain and in the liver.
METHOD
Thirty-four female patients were selected for the trial. Their ages ranged from 26 to 77 (mean age 57). They had suffered from recurrent attacks of endogenous depression for an average period of eight years. All had had E.C.T. previously. A sheet bearing the following fourteen items was scored weekly for each patient on a four-point scale (0 to 3). The items were as follows: feelings of depression, suicidal ideas, ideas of unworthiness, retardation, ideas of reference, loss of appetite, constipation, somatic delusions, inability to sleep, early waking, agitation, daily mood swing, loss of weight and self-neglect. The patients were selected for two groups, A and B, by tossing a coin. A double-blind 704 cross-over trial was carried out so @ that each group formed its own control.
Group A was given phenelzinÃ¨,15 mg. t.i.d. for two weeks and group B was given a placebo of identical appearance t.i.d. for the same period. At the end of two weeks patients in group A were given the placebo and those in group B were given phenelzine for a further two weeks. For the third and last period of two weeks all patients were given phenelzine. It was felt reasonable to limit the trial to a relatively short period since depression can remit spontaneously in a few weeks and existing treatments for depression are often effective fairly rapidly. The patients were seen at the same time each week by both investigators, but the patients of D.S. were assessed by J.T.H. and vice-versa. The trial was controlled by the hospital pharmacist and none of the medical or' nursing staff knew which of the patients were having the drug and which the placebo.
RESULTS
An analysis of the item sheets before and after the trial gave the following results, which includes the effect of both drug and placebo. Made worse . . . .
(14%)
Nine patients (26 per cent.) of the group were discharged from hospital after treatment.
A more detailed analysis of the remission rate produced the following findings:
A. The two groups, A and B, show a remarkable similarity in total number of symptoms (Aâ€"245, Bâ€"244), but the patients in group A showed a greater degree of depression (16 per cent.) and those in group B were much more anxious (25 per cent.). 
E. A Typical Case History:
Miss M.F.J., age 70. She is a conscientious hard-working spinster, who had no history of depression before 1955.Then she had an attack which was characterized chiefly by financialworries and agitation. This attack responded rapidly to E.C.T. and she was discharged from hospital. In 1957 she had a second attack of depression but this one differed from the first in symptomatology. She was depressed and so grossly retarded that she had to be admitted to hospital as a certified patient. She showed marked feelings of depression, ideas of un worthiness, and her sleep and appetite were poor. Agitation and suicidal ideas were present but not prominent. She had no ideas of reference, no mood swings and no somatic delusions. She made a good initial response to E.C.T. but soon relapsed into her state of depression. Two further courses of E.C.T. were given without benefit. She remained in a state of chronic niiserg, being almost speechless with depression. In February, 1959 she started to take pbenelzine 15 mg. t.i.d. and after two weeks' treatment she showed a remarkable degree of improvement. Her relatives were quick to note the change in her appearance, she went home on leave for several week-ends and she was finally discharged in April, 1959, after an illness which had lasted for almost two years.
DIScuSSION
At first glance there would seem to be little to choose between the response to the drug and the response to the placebo. The most important factor appears to be the initial variety of treatment. The greater response is in the first two weeks, irrespective of the form of treatment, drug or placebo. This would seem to imply that there are three possible causes of recovery : drug, placebo and spontaneous remission. There is some evidence however to show that a drug effect is present which is probably greater than the effect of either placebo or spontaneous remission. Examination of Figures 1 and 3 shows that the response to the drug is immediate and that there is a tendency for the drug effect to persist for a little while after the change to placebo. Table III shows a number of symptoms which respond similarly in both groups of patients to the drug and the placebo. These include inability to sleep and early waking, the latter showing a difference of response to drug and placebo in both groups which was statistically significant. If one compares the two groups in the manner shown in Tables IVâ€"Y, again a significant difference is demonstrated between the responses to drug and placebo for the symptoms of inability to sleep and early waking, with the exception of Table V for the symptom of early waking whete the difference is not sufficiently great to be significant. It may be argued that this is not a valid comparison since the groups are not homogeneous. However they are almost similar apart from the differences in agitation and depressive ideas, described above, and one is impressed by the way in which these symptoms of sleep disturbance show a regular pattern of response to drug and placebo. They are commonly improved by the drug and made worse by the placebo. Again some psychiatrists do not accept the view that inability to sleep and early waking are characteristic depressive symptoms ; but the present writers have found these symptoms constantly in these series and are impressed by the constancy of their incidence.
Although the apparent improvement after the total course of treatment is much higher for the psychological symptoms of depression, the nidus of recovery appears to be in the physiological symptoms of inability to sleep and early waking. Once these improve the psychological symptoms remit rapidly. Of interest is the response of the symptoms of loss of appetite and constipation to placebo. It is well known that in general such symptoms respond readily to placebo, but it has been thought always that the loss of appetite and constipation of depressed patients were physiological phenomena and were much more intractable to simple treatments. The treatment of depression presents a difficult problem for statistical evaluation. The illness can remit spontaneously at any time and the course of natural remission can be rapid. Once treatment has begun, the process of spontaneous remission can come into play and add its force to that of the particular treatment. In any event recovery can be swift and it is difficult to achieve a reversal of improve ment either by the use of a drug or placebo after the third or fourth week of treatment. However it is felt that the results of this trial show that there is a valid response of the depressive symptoms of inability to sleep and early waking to the drug phenelzine.
At present E.C.T. is the most widely used form of treatment in depression but its disadvantages, i.e. the risk of fatal outcome (Maclay, 7) and transient memory impairment (Sargant and Slater, 8) , tend to concentrate interest on a search for a simpler, safer form of treatment. Amphetamine is a drug which has been used in depression for many years, but most psychiatrists feel that it offers only temporary relief for symptoms. Indeed it tends to aggravate insomnia and loss of appetite and there is a fair risk of addiction.
Iproniazid is ofdoubtful value since it can produce liver damage and death (Smarr, et a!., 9). Recently, Tofranil (imipramine) has been given a trial in the treatment of depression with some promising results (Delay et a!., 4) but it has exhibited some side-effects, notably skin rashes (Boyd and Forest, 2) . No toxic side-effects ofany description have been noted in this trial ofphenelzine, but it is emphasized that no patient was given the drug for longer than four weeks. Indeed it is the writers' view that if a depressed patient is not going to respond after four weeks of any treatment there is little point in continuing with that treatment.
It is apparent from Figure 1 that there is a good initial response to phenelzine and that there is an appreciable remission of symptoms after two to three weeks of treatment. Since this is the average duration of a course of E.C.T. there is a reasonable case to be made out for comparing phenelzine favourably with E.C.T. However, in the present state of knowledge E.C.T. remains the treatment of choice where the patient is so retarded and stuporose that she is likely to die from starvation.
PHENELZINEIN THE TREATMENTOF ENDOGENOUSDEPRESSION SUMMARY AND CONCLUSIONS
A double-blind cross-over trial has been carried out on 34 female, depressed, in-patients, using a mono-amine oxidase inhibitor, phenelzine and a placebo. Nine (26 per cent.) patients have been discharged, 13 (38 per cent.) have shown great improvement and 14 (41 per cent.) have shown a slight or a moderate improvement. Five patients (14 per cent.) were made worse. The symptoms which gave a valid response to the drug over the placebo were early waking and possibly inability to sleep. Constipation and loss of appetite responded remarkably to the placebo. In view of the apparent absence of side-effects during the four weeks of the trial, the fairly rapid action of the drug and its obvious positive effect on some of the physiological aspects of depression, it is felt that phenelzine has a place in the treatment of this condition.
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